| 中文关键词: 卵巢肿瘤 靶向治疗 贝伐单抗 血管内皮生长因子 |
| 英文关键词:ovarian neoplasms targeted therapy bevacizumab vascular endothelial growth factor |
| 基金项目: |
|
| 摘要点击次数: 1995 |
| 全文下载次数: 1196 |
| 中文摘要: |
| 摘 要：卵巢癌是女性常见的恶性肿瘤。由于其临床症状不典型、易复发等特点，患者的5年生存率较低，且生活质量不甚理想。靶向治疗是继传统方法以外一种有效的新型治疗方法。贝伐单抗是以抑制血管内皮生长因子为作用机制的分子靶向治疗药物的单克隆抗体。本文综述了有关贝伐单抗在卵巢癌中的临床应用及研究进展。 |
| 英文摘要: |
| Abstract：Ovarian cancer is a common female malignant tumor. Because of its atypical clinical symptoms and easy recurrence，5-year survival rate is low，and the quality of life is not very ideal. Target therapy is the traditional method of a kind of effective new treatments. Bevacizumab is inhibition of vascular endothelial growth factor for the mechanism of molecular targeted therapy drugs monoclonal antibodies. This paper reviews the relevant bevacizumab in clinical application and research progress of ovarian cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
